Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830424 | 0.86 | CYP3A4 (0.33) | CYP3A4CYP2D6IDO1PDE2A | |
| SCHEMBL16648469 | 0.79 | PTGDR2 (0.34) | PDE2A | |
| SCHEMBL829759 | 0.78 | PDE2A (0.33) | CYP3A4CYP2D6IDO1PDE2A | |
| SCHEMBL829465 | 0.77 | MEN1 (0.35) | PDE2A | |
| SCHEMBL830877 | 0.69 | NR3C1 (0.31) | — | |
| SCHEMBL30661999 | 0.69 | MGLL (0.39) | PPARAPPARGPPARDCYP3A4CYP2D6 | |
| SCHEMBL25977970 | 0.69 | PPARG (0.43) | PPARAPPARGPPARDHRH4CYP3A4 | |
| SCHEMBL3273222 | 0.68 | VDR (0.46) | PPARAPPARGPPARDPGR | |
| SCHEMBL831060 | 0.68 | CXCR2 (0.34) | NR1H2NR1H3 | |
| SCHEMBL1400639 | 0.68 | ESR1 (0.51) | PPARAPPARGPPARDHRH4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-1773315-B1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | PSEN2, PSEN1, NAT1 | PPARA 164/4885PPARG 157/4885PPARD 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.